Canadian Pacific Kansas City Limited Common Shares vs Medpace Holdings Inc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $83.86 (market cap $73.71B), while Medpace Holdings Inc trades at $602 (market cap $16.87B). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 4.4× Medpace Holdings Inc's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.91% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| CP | MEDP | |
|---|---|---|
Market Cap | $73.71B | $16.87B |
Volume | 2,143,178 | 207,570 |
Sector | Industrials | Health |
52-Week High | $96.69 | $630.19 |
52-Week Low | $68.88 | $393.42 |
Enterprise Value | $91.14B | $16.48B |
Dividend Yield | 0.91% | — |
Typical Hold Time | — | 14 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →